INS and Insulin resistance: Administration of the CCB, metformin, or both together over 12 weeks significantly reduced glucose, insulin, and glycosylated hemoglobin (HbA1c) levels, as well as decreased insulin resistance (HOMA-IR) and increased pancreatic function (HOMA-B) in ZDF animals (Supplementary Table S1).